Mesenchymal stromal cells (MSC) present in the tumor microenvironment [usually named tumor-associated fibroblasts (TAF)] can exert immunosuppressive effects on T and natural killer (NK) lymphocytes, favoring tumor immune escape. We have analyzed this mechanism in colorectal carcinoma (CRC) and found that co-culture of NK cells with TAF can prevent the IL-2-mediated NKG2D upregulation. This leads to the impairment of NKG2D-mediated recognition of CRC cells, sparing the NK cell activation through DNAM1 or FcγRIIIA (CD16). In situ, TAF express detectable levels of epidermal growth factor receptor (EGFR); thus, the therapeutic anti-EGFR humanized antibody cetuximab can trigger the antibody-dependent cellular cytotoxicity of TAF, through the engagement of FcγRIIIA on NK cells. Importantly, in the tumor, we found a lymphoid infiltrate containing NKp46
Mesenchymal stromal cells (MSC) present in the tumor microenvironment [usually named tumor-associated fibroblasts (TAF)] can exert immunosuppressive effects on T and natural killer (NK) lymphocytes, favoring tumor immune escape. We have analyzed this mechanism in colorectal carcinoma (CRC) and found that co-culture of NK cells with TAF can prevent the IL-2-mediated NKG2D upregulation. This leads to the impairment of NKG2D-mediated recognition of CRC cells, sparing the NK cell activation through DNAM1 or FcγRIIIA (CD16). In situ, TAF express detectable levels of epidermal growth factor receptor (EGFR); thus, the therapeutic anti-EGFR humanized antibody cetuximab can trigger the antibody-dependent cellular cytotoxicity of TAF, through the engagement of FcγRIIIA on NK cells. Importantly, in the tumor, we found a lymphoid infiltrate containing NKp46 +
CD3
− NK cells, enriched in CD16 + cells. This population, sorted and cultured with IL-2, could be triggered via CD16 and via NKG2D. Of note, ex vivo NKp46 +
− cells were able to kill autologous TAF; in vivo, this might represent a control mechanism to reduce TAF-mediated regulatory effect on NK cell function. Altogether, these findings suggest that MSC from the neoplastic mucosa (TAF) of CRC patients can downregulate the immune cell recognition of CRC tumor cells. This immunosuppression can be relieved by the anti-EGFR antibody used in CRC immunotherapy.
Keywords: crc, nKg2D, natural killer cells, egFr, antibody-dependent cellular cytotoxicity, cetuximab, TMe inTrODUcTiOn Several reports have shown that mesenchymal stromal cells (MSC) can exert potent immunosuppressive effects leading to the downregulation of T and natural killer (NK) cell responses; indeed, the interaction between MSC isolated from bone marrow and effector lymphocytes can lead to the suppression of T cell proliferation and NK cell cytotoxic activity (1) (2) (3) (4) (5) (6) (7) . In addition, MSC-mediated immunosuppression has been reported to favor tumor growth in animal models (8) . These cells are represented in the tumor microenvironment as tumor-associated fibroblasts (TAF), myofi broblasts, pericytes, adipocytes, lymphatic, and vascular endothelial cells (9, 10) . All these cell types can influence the antitumor immune response and the fate of tumor cells (9) (10) (11) (12) . In normal gut, MSC are a major structural component of crypts, constituting the pericryptal fibroblast sheath (13) . The intestinal crypt is a proliferative compartment maintained by stem cells and some evidences support that colorectal carcinoma (CRC) can emerge at the niche of tissue stem cells (14) . Thus, MSC can play a role in regulating epithelial cell proliferation and differentiation (13) (14) (15) ; more importantly, some reports have indicated MSC as an attractive target for antitumor vaccine (16) (17) (18) (19) . Recently, it has been shown in a murine model that targeting TAF and tumor cells is effective in modifying tumor microenvironment. Indeed, the use of tumor cells expressing fibroblast activation protein as a vaccine resulted in the elimination of solid tumor and impairment of vascular dissemination. Importantly, this effect was accompanied by tumor infiltration of CD8 + T cells, reduction of TAF number and inhibition of the recruitment of immunosuppressive cells within the tumor (16) (17) (18) (19) . Based on these considerations, it is relevant to determine whether MSC derived from CRC mucosa display immunosuppressive properties. Indeed, it has been shown that TAF in melanoma patients may exert potent inhibiting effects on NK cell responses (20) . In addition, TAF from head and neck cancer can inhibit T cell proliferation, further suggesting that mesenchymal cells can regulate the antitumor immune response (21) . These findings indicate that also in humans MSC can be a suitable target for cancer therapies aimed to revert their immunosuppressive effect and allow the development of NK cell-mediated antitumor response (9) . NK cells can bind to tumor targets through the interaction of lymphocyte function associated (LFA)1 and intercellular adhesion molecule (ICAM)1 expressed on tumor cells (22) . This interaction leads to the engagement of NK cell activating receptors, including NKG2D or DNAM1 (23, 24) , which bind to their ligands on tumor cells triggering their killing (23) (24) (25) . In particular, CRC cells can express the NKG2D ligands (NKG2D-L) MICA and ULBPs, or the DNAM1 ligands (DNAM1-L) poliovirus receptor (PVR) and nectin-2: NKG2D-NKG2D-L and DNAM1-DNAM1-L interaction would lead to CRC cell recognition and killing by NK effector cells (26) . NK cells can kill tumor cells also by the triggering of antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcγRIIIA (CD16) (27) . This mechanism has been exploited in anti-cancer immunotherapy with the anti-epidermal growth factor receptor (EGFR) antibody cetuximab in KRAS wild type CRC (27, 28) . Thus, the presence of functional NK cells can contribute both to CRC cell control and to the success of immunotherapy.
In this work, we show that: (1) TAF downregulate the NKG2D-mediated killing of CRC and prevent the IL-2 induced NKG2D upregulation on NK cells. (2) TAF express EGFR and can be killed by NK cells in ADCC triggered via the anti-EGFR antibody cetuximab. (3) NKp46 + CD3 − NK cells found at the tumor site, sorted and cultured with IL-2, can kill autologous TAF.
MaTerials anD MeThODs

Monoclonal antibodies (mabs) and reagents
Anti-NKG2D (MAB139, IgG1), anti-DNAM1 (MAB666, IgG1), anti-CD32 (MAB1330, IgG2a), anti-CD64 (FAP12571, IgG1), anti-CD56 (301040, IgG2b), anti-CD90 (FAB2067p, IgG2a), anti-PVR (MAB25301, IgG1), anti-ULBP1 (MAB1380, IgG2a), ULBP2 (MAB1298, IgG2a), ULBP3 (MAB15171, IgG2a), and anti-CD146 (MAB932, IgG1) mAbs were purchased from R&D System (Minneapolis, MN, USA). The anti-CD3 mAb (JT3A, IgG2a), the anti-CD16 mAbs (NK1, IgG1 and NK54, IgG2a), the anti-CD18 mAb (70H12, IgG2a), the anti-CD54 mAb (ICAM1, clone SM89, IgM), the anti-MICA (M320, IgM), and the anti-CD45 (T205, IgM) were obtained in our laboratory (4) . The PE-anti-NKp46 (9E2, IgG1) was purchased from Miltenyi biotech (Germany, EU); Alexafluor488-anti-CD45 (HI30, IgG1), PE-Cy7-anti-NKp46 (9E2, IgG1), PE/Dazzle-anti-CD3 (UCHT1, IgG1), PE-Cy5 anti-CD56, Pacific Blue-anti-CD16, and anti-NKG2A (16A11, IgG2b) mAbs were from BioLegend (San Diego, CA, USA). The anti-SH2 (CD105, IgG1), the anti-SH3 (CD73, IgG2b), the anti-CD11a (LFA1α, TS1.22, IgG1), and the anti-CD18 (LFA1β, TS1.18, IgG1) producing hybridomas were purchased from the American Type Culture Collection (Manassas, VA, USA). Anti-vimentin mAb was from Dako Cytomation (clone V9) and anti-collagen I was from Novus Biologicals LLC (Littelton, CO, USA, clone NB600-450). The therapeutic anti-EGFR cetuximab and anti-CD20 rituximab humanized antibodies were from the Antiblastic Drug Unit of the Policlinico San Martino (Genoa, Italy) as the leftover of the dose delivered to patients for immunotherapy. Complete medium was composed of RPMI1640 (Thermo Fisher Scientific, Carlsbad, CA, USA) with 10% of fetal calf serum (FCS, Sigma) supplemented with 1% antibiotics (penicillin and streptomycin) and 1% l-glutamine (Thermo Fisher Scientific).
crc cell lines and cell isolation From Tumor specimens CRC cell lines Caco2, HT29, HCT15, SW480, DLD1, HCT116, LS180, WiDr, LoVo, Colo205, Colo320 DMF, SW620, T84, and SW48 were from cell bank of the IRCCS (kind gift of Blood Transfusion Centre, Dr. Barbara Parodi), and for the three CRC cell lines used in cytolytic assays (Caco2, HCT15, and SW480), the correct identification was determined with STR DNA profile. Peripheral blood mononuclear cells (PBMC) were obtained from venous blood samples of healthy donors of the Transfusional Centre of the Policlinico San Martino (upon signed institutional informed consent, according to a procedure defined by the Regional Ethic Committee, CONSAZH780148/17/07/2015) after Ficoll-Hypaque density gradient separation (29) . NK cells from PBMC, or from tumor tissue suspensions (see below), were obtained using the corresponding RosetteSep negative separation kit (StemCell Technologies SARL, Grenoble, France). The purity of NK cell populations ranged from 75 to 95% for the expression of CD56, 65 to 85% CD16 Purity of cell sorting was 98.5% (two anti-CD3 mAbs, JT3A and UCHT1, were used to define the purity of the bulk population as CD3 − NK cells). Cells were then put in culture in RPMI1640 supplemented with 10% FCS and 10 ng/ml IL-2 (30 IU/ml, Miltenyi Biotech GmbH, Bergisch, Gadbach, Germany, specific activity 3 × 10 6 IU) on irradiated PBMC as feeder cells in U-bottomed plates. Cell cultures were then split when evident cell growth was microscopically detected, checked for the expression of NKP46 on day 25 (>90%) and used in functional assays. Generation of primary MSC lines was obtained after mincing of both CRC mucosa (TAF) and normal appearing mucosa, sampled at least 10 cm from the tumor [fibroblasts (FB)], and enzyme digestion as previously reported (31) . Cell suspensions were seeded in culture wells and after 36 h non-adherent cells were removed. Adherent cells showing a fibroblast-like morphology were cultured for additional 7 day. At confluence, cell cultures were split and expanded as described (32) . Phenotype for the indicated markers was analyzed at different time points and the expression of these markers was similar along the culture period of 2 months. Thus, MSC/TAF or MSC/FB expressed CD73, CD90, CD105, CD146, collagen I, vimentin ( Figure S1 in Supplementary Material), bone sialoprotein, CD44, CD29, class I human leukocyte antigen (HLA-I), prolyl-4-hydroxylase, alkaline phoshatase, fibroblast activation protein, smooth muscle actin, the transcription marker SOX-2, and osteopontin but not CD45, CD31, CD33, CD34, CD3, CD2, CD16, CD14, ICAM2, ICAM3, CD80, CD86, CD83, and HLA-DR (31, 32) . Nanog, OCT3-4 SSE-4, and TRA-1-60 stem cell markers were negative in both types of MSC (not shown).
cytotoxicity assay
Cytolytic assay was performed as described previously (32, 33) . Target cells were colon mucosa-derived MSC (TAF or FB) or the CRC cell lines Caco2, HCT15, and SW480. All these targets were cultured in RPMI 1640 24 h prior to the cytolytic assay and used in cytotoxicity experiments at the effector:target (E:T) ratio of 20:1. Reverse cytotoxicity was performed using the anti-NKG2D, the anti-DNAM1, the anti-CD16, the anti-NKp46, the anti-CD3, or the anti-CD56 mAbs, all at 2 µg/ml, and the FcγR positive murine P815 cell line [antibody-triggered cellular cytotoxicity (ATCC)], as described (33, 34) at 5:1 E:T ratio. Cells were labeled with 51 Cr, washed, and seeded with effector cells. 51 Cr-specific release was calculated as: experimental release (counts) − spontaneous release (counts)/maximum release (counts) − spontaneous release (counts). Maximum and spontaneous release were calculated as described (33, 34) . In some experiments, saturating amounts of mAbs to NKG2D or DNAM1 or LFA1 and ICAM1 (2 µg/ml) were added. Target cells were also tested for their reactivity with the Fc chimeras (soluble receptors fused with the Fc of human immunoglobulins) NKG2D-Fc, DNAM1-Fc, NKp30-Fc, NKp44-Fc, and NKp46-Fc (R&D System), to determine the expression of ligands for these NK cell-activating receptors. NKp30-Fc, NKp44-Fc, and NKp46-Fc did not react with target cells (not shown). The expression of NKG2D-L and DNAM1-L on target cells was further confirmed with specific antibodies to MICA and ULBP3 (NKG2D-L) or CD115 (poliovirus receptor, PVR, as DNAM1-L) by immunofluorescence and FACS analysis ( Figures S2 and S3 in Supplementary Material). In ADCC, the anti-EGFR cetuximab or the anti-CD20 rituximab humanized antibody (2 µg/ml) were added at the onset of the cytolytic assay, performed at the E:T ratio of 5:1. In another series of experiments, sorted NKp46 +
CD3
− cells were expanded in IL-2-containing medium and used either in ATCC as above or in cytotoxicity assay against HLA-I + Caco2 or HLA-I − HCT15 CRC cell line in a 51 Cr release assay, or against autologous TAF: in this case, the crystal violet viability assay was used to evaluate target cell damage (35) .
immunofluorescence and cytofluorimetric analysis
Immunofluorescence on either lymphocytes or colon MSC or CRC cell lines was performed with the indicated fluorophoreconjugated mAbs or primary mAbs followed by the addition of anti-isotype-specific goat anti-mouse (GAM) antisera (Southern Biotechnology, CA, USA) conjugated with AlexaFluor647 (Invitrogen, Thermo Fisher Scientific) as indicated. Control samples were stained with fluorophore-conjugated isotype control mAbs or isotype-matched irrelevant mAb (Becton Dickinson, Paolo Alto, CA, USA) followed by anti-isotype specific GAM-AlexaFluor647. To assess the reactivity of Fc chimeras, cetuximab or rituximab an anti-human immunoglobulin antiserum conjugated with AlexaFluor647 was used (Thermo Fisher Scientific). Samples were run on a CyAn ADP cytofluorimeter (Beckman-Coulter, Pasadena, CA, USA), analyzed with the Summit computer program (Beckman-Coulter), and are expressed as Log fluorescence intensity vs number of cells.
co-cultures of colon TaF, FB, and nK cells 2 × 10 4 /sample MSC were co-cultured with NK cells at the NK:MSC ratio of 5:1 in 96W-microwell flat-bottomed plates (this was the first NK:MSC ratio at which an evident inhibition of NKG2D upregulation was detected; this ratio was determined in preliminary titration experiment starting from NK:MSC ratio of 20:1, 10:1, 5:1, 2:1, and 1:1) with 10 ng/ml IL-2 for 6 days and then analyzed for the expression and function of NKG2D and DNAM1 activating receptors by immunofluorescence and reverse cytotoxicity [or antibody-triggered cellular cytotoxicity (ATCC)]. In some experiments, NK cells were seeded on Millicell transwell (TW) with 0.3 µm pores (Millipore Corporation, Billerica, MA, USA) put into 24w plates with TAF or FB (6 × 10 4 /sample, the same number/area of culture well used for co-cultures of NK cells in direct contact with MSC) seeded in the lower chamber of the well, to avoid the contact with NK cells. Supernatants (SN) were collected from TAF cultures after 48 h for transforming growth factor (TGF)β measurement by ELISA (eBioscences, Thermo Fischer Scientific), after treatment for 10 min of each SN with 1N HCl as described (36) . Results were normalized to a standard curve and expressed as picogram per milliliter.
immunohistochemistry Paraffin-embedded samples from six CRC patients were analyzed. Immunohistochemistry was performed on 6-μm-thin sections, deparaffinized in xylene, and treated with Peroxo-Block (Thermo Fisher Scientific) to quench endogenous peroxidase, followed by Ultra V Block reagent (Ultravision Detection System, BioOptica, Thermo Fisher Scientific). Cetuximab and rituximab humanized antibodies were biotinylated using EZ-Link Sulfo-NHS-LCBiotin (Thermo Fisher Scientific), according to the manufacturer's instruction. These reagents were then added overnight to the slides, compared to the anti-vimentin mAb or to an isotypic unrelated antibody used as negative control (Dako Cytomation, Milan, Italy). Slides were then washed and incubated for 30 min with HRP-conjugated streptavidin (Thermo Fisher Scientific) and the reaction was developed using 3,3′-diaminobenzidine as chromogen. Subsequently, slides were counterstained with hematoxylin, cover-slipped with Eukitt (Bioptica, Thermo Fisher Scientific), and analyzed under an Leica DM MB2 microscope (Wetzlar, Germany) equipped with a charged coupled device camera (Olympus DP70, Tokyo, Japan) with a 20× or 40× objective.
cDna reverse Transcription and Quantitative real-Time Pcr (Q-rT-Pcr)
Natural killer cells cultured with IL-2 and colon MSC at the NK:MSC ratio of 5:1 were harvested at different time points (0, 3, 6, and 24 h) and analyzed for the expression of NKG2D receptor mRNA by Q-RT-PCR, as described (35) . RNA was extracted with TriPure (Roche Diagnostic, Milan, Italy) and cDNA synthesis was performed with random primers. To verify quantitative Q-RT-PCR efficiency, decreasing amounts (50, 10, and 0.1 ng) of normal RNA were used for CT titration. Primers and probes for NKG2D were purchased by Applied Biosystem (Hs00183683_m1, Thermo Fisher Scientific). Q-RT-PCR was performed on the 7900HT FastRT-PCR system with the fluorescent Taqman method and normalized to 18s (Hs9999901_s1, Thermo Fisher Scientific). After subtracting the threshold cycle (CT) value for 18s from the CT values of target genes, results were expressed as 2 −ΔΔCT expression ratio following MIQE guidelines.
statistical analysis
Data were analyzed by applying the two-tailed Student's t test at 99% confidence, or the non-parametric two-tailed t test (MannWhitney), using the GraphPad Prism software (La Jolla, CA, USA).
resUlTs
TaF isolated From crc inhibit nK cell antitumor activity
We first analyzed the phenotype of MSC isolated from the tumor (TAF) and from tumor free mucosa (FB). We found that TAF Figure S3 in Supplementary Material). Moreover, Caco2 was selected as it does not display any mutation of KRAS, BRAF, and PI3K genes, while HCT15 and SW480 are mutated for KRAS (28) . The Fc-NKp30, Fc-NKp44, and Fc-NKp46 chimeras did not react with the three analyzed CRC cell lines (not shown).
We found that IL-2-activated NK cells derived from cocultures with tumor-derived MSC (NK/TAF) exerted lower cytotoxicity of Caco2, HCT15, and SW480 CRC cell lines, compared to NK cells cultured with IL-2 alone that were efficiently able to lyse CRC ( Figures 1A-C , NK/TAF vs NK in each panel). NKG2D, DNAM1, and LFA1 molecules were all involved in CRC recognition and killing; indeed, the addition of mAbs against these molecules efficiently reduced target cell lysis and the simultaneous covering of all these receptors almost abolished NK cell mediated cytotoxicity (Figures 1A-C) . Of note, the anti-NKG2D mAb did not inhibit tumor cell lysis exerted by NK/TAF cells ( Figures 1A-C , dark vs light gray), suggesting that NKG2D-mediated recognition is impaired, at variance with anti-DNAM1 or anti-LFA1 mAbs ( Figures 1A-C , white whiskers). These results indicate that CRC cells are recognized and killed by NK cells through the interaction of LFA1, NKG2D, and DNAM1 with their ligands expressed on target cells; further, TAF can affect NK cell mediated lysis of CRC cell lines, mainly interfering on the function of NKG2D. Noteworthily, NK cells harvested from NK/TAF co-cultures, could still be triggered by cetuximab, even at a very low E:T ratio (5:1), and exert ADCC against Caco2, HCT15, and SW480 cell lines (Figures 1D-F) .
It is of interest that the surface expression of NKG2D was markedly reduced in NK cells recovered from co-cultures with TAF (NK/TAF, Figure 2A , one representative experiment and Figure 2B , mean of six experiments with six different TAF); this decrease was not evident when NK and MSC were co-incubated for the same time but separated by a transwell system (NK TW/ TAF, Figures 2A,B) . No effect on CD16 (Figure 2A) or DNAM1 or LFA1 (not shown) expression was observed. Of note, co-incubation with TAF inhibited in NK cells the upregulation of mRNA coding for NKG2D triggered by IL-2 ( Figure 2C) ; this finding suggests that the downregulation of NKG2D surface expression is mainly due to the impairment of the IL-2 mediated upregulation of mRNA for NKG2D and consequent reduced synthesis of NKG2D protein. More importantly, TGFβ, a cytokine involved in the downregulation of NKG2D protein expression (34) was detected in the SN of cultured TAF from six different patients ( Figure 2D ). In turn, specific inhibitors of prostaglandin (PG) E2 synthesis or indoleamine dioxigenase activity did not affect the TAF-mediated reduction of NKG2D expression (not shown). Finally, we observed that NK cells co-cultured with TAF showed a markedly lower cytolytic activity triggered by the NKG2D receptor in reverse killing (ATCC) against the P815 cell line, compared to that of NK cells cultured without TAF (Figure 2E) . In this assay, cytolytic activity is due to the activation on the effector NK cell of a receptor recognized by a specific mAb that, in turn, binds to the Fc receptor of P815 cells acting as a bridge between effector and target. It is of note that triggering of NK cells through the CD16 receptor was very strong and similar in NK cells recovered from co-cultures with TAF to that displayed by NK cells alone ( Figure 2E ).
crc-Derived TaF express egFr and can Be Targeted by the anti-egFr humanized antibody cetuximab
As TAF/NK cross talk does not interfere with CD16-triggered NK cytotoxicity, we analyzed if the EGFR humanized antibody cetuximab can recognize MSC and lead to their killing. We have described that CRC-derived TAF primary cultures express EGFR (35) : here, we confirmed that cetuximab can bind EGFR on these cells, either TAF or FB ( Figure 3A shows one representative experiment out of six cases showing >90% positive cells with a MFI range of 65-130, not shown). Of note, we found that cetuximab reacted with TAF (identified by vimentin staining, Figures 4D,I ,P) at the tumor site in CRC ( Figure 4B , enlarged in Figure 4C ) and stained also FB in nonneoplastic areas ( Figure 4G , enlarged in Figure 4H ). Epithelial cells expressed EGFR as well (Figures 4N,O) . The specificity of cetuximab reaction with TAF in tumor specimens was also supported by the finding that the isotype-matched antibody Figure 3A , CD64, CD32, and CD16). Staining with only anti-human immunoglobulin antiserum did not give any reactivity in CRC spacimens ( Figures 4A,F,M) . Thus, we analyzed whether cetuximab can trigger the killing of CRC TAF or FB through the recognition of EGFR and the engagement of the CD16 receptor on NK cells. We found that cetuximab can induce peripheral blood freshly isolated NK cells to exert ADCC of TAF ( Figure 3B ). This effect was dependent on the engagement of CD16 on NK cells as the covering of this receptor with a specific anti-CD16 mAb, but not that of CD56, strongly inhibit cetuximab-mediated ADCC of TAF ( Figure 3C) . Similar results were obtained using FB (not shown). NK cells activated with IL-2 can also recognize and kill both TAF and FB, while freshly isolated NK cells exerted a very low cytotoxic effect (about 20%), in the absence of cetuximab, even at high E:T ratio (20:1, Figures 3D,E) . The cytolytic function of activated NK cells was dependent on the interaction of LFA1, NKG2D, and DNAM1 with their ligands, as specific antibodies to these molecules can inhibit TAF (Figure 3F ) or FB ( Figure 3G ) lysis and the simultaneous covering of all these three NK cell receptors can abolish cell lysis (Figures 3F,G) . These findings suggest that TAF can be Cr-specific release and are the mean with boxes and whiskers min to max of six independent experiments with matched TAF and FB from six different patients. ***p < 0.0001; **p < 0.001. 
CD3
− cells (98.5% purity) were expanded with IL-2 and used in ATCC against P815 (E:T ratio 2.5:1), in crystal violet assay with autologous TAF or in cytotoxicity assay (E:T ratio 10:1) against Caco2 or HCT15 CRC cell lines. These cell populations expressed CD16, NKG2D, DNAM1, and NKp46 ( Figure 6A) . As shown in Figure 6B , NKp46
− cells derived from four out of five CRC specimens could be elicited to activate ATCC via CD16, NKp46, DNAM1, and NKG2D (the anti-CD3 mAb used as negative control did not increase the spontaneous activity, identified as CTR in the figure), indicating that this cell population is potentially cytotoxic. Three cases (Figure 6 , OMCR16-030, black circles and column; OMCR16-082, gray circles and column; and OMCR16-001, white circles and column) were studied in more detail as autologous TAF have been derived. OMCR16-030 and OMCR16-082 NKp46 + CD3 − cells could kill most autologous TAF; by contrast, NKp46
+ CD3 − cells derived from OMCR16-001 population were not effective ( Figure 6C) . To explain this different behavior, we tested all the NKp46 + CD3 − cell populations for the expression of some HLA-class I inhibitory receptors, such as KIR2D and NKG2A (5, 22, 37) . We found a higher percentage of cells expressing the inhibitory molecule NKG2A among the NKp46 + CD3 − population derived from OMCR16-001 CRC, compared to the same population sorted from OMCR16-030 and OMCR16-082 CRC (Figure 6D) . Moreover, the MFI ratio vs the negative control (measure of the intensity of NKG2A expression) was more than twofold or threefold in OMCR16-001 NKp46 +
− cells. As NKG2A inhibitory signal is elicited by binding to HLA-I, we analyzed the ability of the different NKp46 + CD3 − cell populations to lyse HLA-I + (Caco2) or HLA-I − (HCT15) CRC cell lines. As shown in Figure 6E , NKp46 + CD3 − cells from OMCR16-001 case did not kill Caco2 (Figure 6E , upper graph, white circles) but was able to lyse HCT15 (Figure 6E , lower graph, white circles), at variance 
DiscUssiOn
Here, we show that TAF from CRC reduce the NKG2D expression levels, through a direct cell-to-cell contact, and impair the NKG2D-mediated triggering of tumor cell lysis, sparing ADCC.
Of note, the anti-EGFR therapeutic antibody cetuximab can overcome NK cell impairment, triggering the CD16-mediated ADCC of MSC.
In the tissue microenvironment, lymphocytes can be localized in contact with TAF, besides carcinoma cells, thus making possible that a negative signal impairs NK cell-mediated antitumor immune response in vivo (38) (39) (40) (41) . We found in the tumor a lymphoid infiltrate containing NKp46 +
CD3
− NK cells, according to other reports (42, 43) . This population is enriched, in the tumor areas, in CD16 + cells, suggesting that ADCC can be elicited by humanized Ab-based therapy.
Along this line, NK cell isolated from the tumor and cultured with IL-2, could still be triggered via CD16, besides through the engagement of other NK cell activating receptors, including NKG2D. It is of note that sorted NKp46 +
− cells were able to kill autologous TAF; in vivo, this might represent a control mechanism to reduce TAF-mediated regulatory effect on NK cell function. In turn, the downregulation of NKG2D activation would be a mechanism to control NK cell-mediated recognition of MSC; this mechanism would limit the damage of NK cells to healthy FB. More importantly, the finding that resting peripheral blood NK cells can be triggered to kill MSC by cetuximab suggests an additional potential therapeutic effect of the humanized Ab to restore a full cytotoxic response against CRC (44) (45) (46) . On the other hand, the effect of cetuximab administration in CRC patients might result in a lower therapeutic effect on the primary tumor due to the presence in situ, as we have shown by immunochemistry, of TAF that express EGFR and can subtract the antibody, thus reducing its availability (44) (45) (46) . Cetuximab would be more efficacious in the metastatic tumor, where cancer cells are no longer protected by colon MSC. Nevertheless, we demonstrated that cetuximab is able to trigger NK cell-mediated ADCC, either against tumor cells or against TAF, thus potentially overcoming MSC-mediated immunosuppression.
We have also highlighted that both MSC and CRC cells are recognized by NK lymphocytes through the same receptors, namely LFA1, NKG2D, and DNAM1. This share of receptor molecules can have a role in favoring the escape of tumor cells from NK cell mediated killing. Indeed, in the tumor NK cells can bind to either CRC cells or MSC, instead of targeting primarily tumor cells and this can divert the antitumor immune response. At variance with our data, it has been shown that NCR, besides NKG2D and DNAM1 (47) , are involved in the killing of CRC cells (48) ; however, in this report cancer initiating cells, but not the unselected tumor cell populations, were lysed through NCR. In addition, other authors described that reactivity with Fc-NCR becomes evident only when CRC cell lines are infected with parvovirus (49) . Thus, our findings that the Fc-NCR chimeras do not react with the CRC cell lines analyzed, would suggest that different surface molecules are involved in the killing of cancer stem cells or virus-infected cells, compared to the large majority of tumor cells.
We noted that MSC from both carcinoma (TAF) and tumor free colon mucosa (FB) showed a similar behavior suggesting that the ability of inhibiting lymphocyte-mediated activities is an intrinsic and basic feature of MSC. A limitation to this interpretation of our results is represented by the fact that, to achieve a stock of cells for functional experiments, MSC were seeded in vitro and expanded in culture (4, 29, 31) , leading to the loss of features, characterizing TAF or FB, present in situ. It has been reported that TAF from melanoma lesions can inhibit NK cell activation better than skin FB isolated from healthy donors (20) ; this inhibiting effect is reported to depend on the production of PGE2 during NK-TAF interaction. Our results indicate that TAF from CRC, matched with FB from the tumor free mucosa of the same patient, do not show different phenotypic or functional characteristics. However, in our study also FB come from a tissue potentially subjected to inflammatory factors released in the tumor and in the surrounding microenvironment, so that they might be considered not entirely healthy cells. These discrepancies could also be related to the use, in the cited report, of unmatched skin FB. Indeed, NK cells are sensitive to the inhibitory signal delivered by HLA-I (50, 51). Thus, the effect of FB from different donors on the same NK cell population, and vice versa, may depend on the fact that this population bear inhibiting HLA-I receptors at the cell surface that recognize different HLA-I alleles on FB. In support to this, we found that tumor-derived NK cells expressing high levels of the inhibitory receptor NKG2A did not aggress autologous TAF nor HLA-I + CRC cells. In addition, we did not identify PGE2 as one of the factors responsible for inhibiting signals delivered to NK cells; rather, TGFβ released by MSC seems to be the factor potentially implied. This would suggest that the molecular mechanism underlying stromal-mediated inhibition is not the same for different tissue districts. According to our data, it has been reported that TGFβ can impair the IL-2-mediated upregulation of NKG2D mRNA (52) (53) (54) . Furthermore, as demonstrated by experiments with millicell transwell chambers, the downregulation of NKG2D on NK cells was not detected when NK cells and MSC were not in direct contact and only soluble molecules present in co-culture supernatant could bind to NK cells. Thus, the reduced NKG2D surface expression and function is likely due to the effect of TGFβ rather than to soluble ligands which cover NKG2D molecule, affecting antibody reactivity (55) .
In conclusion, our findings support that MSC may be a target for immunotherapies designed to favor antitumor lymphocyte effector functions (9) ; the use of cetuximab in anti-CRC therapeutic schemes should be useful to overcome MSC-mediated immunosuppression.
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